Experimental MERS vaccine shows promise in human trial
NCT ID NCT04588428
Summary
This study tested an experimental vaccine called INO-4700 designed to protect against Middle East Respiratory Syndrome (MERS). Researchers enrolled 192 healthy volunteers to evaluate the vaccine's safety and whether it triggered an immune response. Participants received either the vaccine or a placebo through a special injection method that uses brief electrical pulses to help the body respond.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS (MERS-COV) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ahero Clincal Trials Unit
Kisumu, 40100, Kenya
-
American University of Beirut Medical Center
Beirut, Lebanon
-
Clinical Research Center, Irbid Specialty Hospital (CRC/ISH)
Irbid, 21110, Jordan
-
Hammoud Hospital University Medical Center
Saida, Lebanon
-
Kenya Medical Research Institute (KEMRI)/Walter Reed Project (WRP)
Kericho, 20200, Kenya
-
Pharmaceutical Research Center / Jordan University of Science and Technology
Irbid, 22110, Jordan
Conditions
Explore the condition pages connected to this study.